Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

47.84 -0.42 (-0.87%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,763,060
Open 48.44
Bid (Size) 47.82 (1)
Ask (Size) 47.90 (5)
Prev. Close 48.26
Today's Range 47.70 - 48.55
52wk Range 47.58 - 70.94
Shares Outstanding 2,222,113,553
Dividend Yield 4.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels. 
Via The Motley Fool

Performance

YTD
-9.33%
-9.33%
1 Month
-7.27%
-7.27%
3 Month
-4.28%
-4.28%
6 Month
-15.85%
-15.85%
1 Year
-31.88%
-31.88%

More News

Read More
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Peering Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
Via Benzinga
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Via Benzinga
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
Via The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Via The Motley Fool
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
Via Benzinga
Exposures Product Safety
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
Via Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
Via The Motley Fool
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
From Bristol Myers Squibb
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
Via InvestorPlace
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.